| (Values in U.S. Thousands) | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 |
| Sales | 36,550 | 30,170 | 12,380 | 19,210 | 20,840 |
| Sales Growth | +21.15% | +143.70% | -35.55% | -7.82% | +146.21% |
| Net Income | -150,720 | -84,650 | -76,130 | -39,900 | 2,330 |
| Net Income Growth | -78.05% | -11.19% | -90.80% | -1,812.45% | -92.85% |
Prometic Life Scienc (PFSCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Liminal BioSciences Inc. is a biotechnology company. It engages in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. The company's product pipeline consists of PBI-4050, which are in clinical stage. Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is based in Laval, Canada.